Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 3
2003 6
2004 1
2005 1
2006 2
2008 1
2009 3
2010 5
2011 7
2012 6
2013 4
2014 4
2015 3
2016 5
2017 6
2018 7
2019 9
2020 5
2021 6
2022 3
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

78 results

Results by year

Filters applied: . Clear all
Page 1
Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.
Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, Hochmair MJ, Özgüroğlu M, Ji JH, Voitko O, Poltoratskiy A, Ponce S, Verderame F, Havel L, Bondarenko I, Kazarnowicz A, Losonczy G, Conev NV, Armstrong J, Byrne N, Shire N, Jiang H, Goldman JW; CASPIAN investigators. Paz-Ares L, et al. Lancet. 2019 Nov 23;394(10212):1929-1939. doi: 10.1016/S0140-6736(19)32222-6. Epub 2019 Oct 4. Lancet. 2019. PMID: 31590988 Clinical Trial.
Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.
Goldman JW, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, Hochmair MJ, Özgüroğlu M, Ji JH, Garassino MC, Voitko O, Poltoratskiy A, Ponce S, Verderame F, Havel L, Bondarenko I, Każarnowicz A, Losonczy G, Conev NV, Armstrong J, Byrne N, Thiyagarajah P, Jiang H, Paz-Ares L; CASPIAN investigators. Goldman JW, et al. Lancet Oncol. 2021 Jan;22(1):51-65. doi: 10.1016/S1470-2045(20)30539-8. Epub 2020 Dec 4. Lancet Oncol. 2021. PMID: 33285097 Clinical Trial.
Antiangiogenic therapies for malignant pleural mesothelioma.
Yano S, Li Q, Wang W, Yamada T, Takeuchi S, Nakataki E, Ogino H, Goto H, Nishioka Y, Sone S. Yano S, et al. Among authors: goto h. Front Biosci (Landmark Ed). 2011 Jan 1;16(2):740-8. doi: 10.2741/3716. Front Biosci (Landmark Ed). 2011. PMID: 21196199 Free article. Review.
Radiation-associated Angiosarcoma Presenting as Massive Pleural Effusion.
Ogino H, Tobiume M, Kagawa K, Kawano H, Sakaguchi S, Saijo A, Matsumoto D, Takizawa H, Morikawa Y, Bando Y, Goto H, Nokihara H, Nishioka Y. Ogino H, et al. Among authors: goto h. Intern Med. 2022 May 1;61(9):1393-1397. doi: 10.2169/internalmedicine.8195-21. Epub 2021 Oct 12. Intern Med. 2022. PMID: 34645765 Free PMC article.
Intractable diffuse pulmonary diseases: Manual for diagnosis and treatment.
Homma S, Ebina M, Kuwano K, Goto H, Sakai F, Sakamoto S, Johkoh T, Sugino K, Tachibana T, Terasaki Y, Nishioka Y, Hagiwara K, Hashimoto N, Hasegawa Y, Hebisawa A; Ministry of Health, Labour and Welfare, the Study Group on Diffuse Pulmonary Disorders, Scientific Research/Research on Intractable Diseases, and Japanese Respiratory Society. Homma S, et al. Among authors: goto h. Respir Investig. 2021 Jan;59(1):8-33. doi: 10.1016/j.resinv.2020.04.004. Epub 2020 Jul 2. Respir Investig. 2021. PMID: 32622842
Prevention of Pemetrexed-Induced Rash Using Low-Dose Corticosteroids: A Phase II Study.
Sakurada T, Nokihara H, Koga T, Zamami Y, Goda M, Yagi K, Hamano H, Aizawa F, Ogino H, Sato S, Kirino Y, Goto H, Nishioka Y, Ishizawa K. Sakurada T, et al. Among authors: goto h. Oncologist. 2022 Jul 5;27(7):e554-e560. doi: 10.1093/oncolo/oyab077. Oncologist. 2022. PMID: 35325241 Free PMC article. Clinical Trial.
Blockade of PD-1/PD-L1 Pathway Enhances the Antigen-Presenting Capacity of Fibrocytes.
Afroj T, Mitsuhashi A, Ogino H, Saijo A, Otsuka K, Yoneda H, Tobiume M, Nguyen NT, Goto H, Koyama K, Sugimoto M, Kondoh O, Nokihara H, Nishioka Y. Afroj T, et al. Among authors: goto h. J Immunol. 2021 Mar 15;206(6):1204-1214. doi: 10.4049/jimmunol.2000909. Epub 2021 Jan 27. J Immunol. 2021. PMID: 33504617 Free PMC article.
Thymidine Catabolism as a Metabolic Strategy for Cancer Survival.
Tabata S, Yamamoto M, Goto H, Hirayama A, Ohishi M, Kuramoto T, Mitsuhashi A, Ikeda R, Haraguchi M, Kawahara K, Shinsato Y, Minami K, Saijo A, Hanibuchi M, Nishioka Y, Sone S, Esumi H, Tomita M, Soga T, Furukawa T, Akiyama SI. Tabata S, et al. Among authors: goto h. Cell Rep. 2017 May 16;19(7):1313-1321. doi: 10.1016/j.celrep.2017.04.061. Cell Rep. 2017. PMID: 28514652 Free article.
78 results